Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from December 2019, including:
- The Solicitor General, on behalf of the US, asserts that the Supreme Court’s Section 101 precedent
creates “substantial uncertainty” requiring clarification - The Federal Circuit holds that there is no single entity equirement for infringement under section 271(g)
- A district court holds that, under certain circumstances, an anticipatory reference is not necessarily “but-for” material under an inequitable conduct analysis
